RPS6KA3 and melanoma: Indeed, the increased RSK activity in vemurafenib resistant melanoma cells went along with elevated levels of PS102-YB-1 not only in the cytoplasm, but especially in the nuclear enriched fractions of the resistant cells compared to the sensitive parental cells (Figure 5A).